CONMED Corporation (CNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

CONMED Corporation (CNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

CONMED Corporation Announces Chief Financial Officer Transition

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the departure of Todd Garner from his role as Chief Financial Officer effective March 15, 2026. To ensure a smooth and orderly transition, Mr. Garner will remain with the Company in an advisory capacity through November 2, 2026. CONMED has initiated a comprehensive search process, supported by a leading executive search firm, to identify its next Chief Financial Officer. “On behalf of our Board and leadership team, I.

Business Wire • Jan 8, 2026

CONMED Corporation to Announce Fourth Quarter 2025 Financial Results on January 28, 2026

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the fourth quarter 2025 after the market close on Wednesday, January 28, 2026. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed.

Business Wire • Jan 5, 2026

CONMED Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Patrick J. Beyer, President and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT (6:00 p.m. ET) on Monday, January 12, 2026 in San Francisco, CA. A live audio webcast of the presentation will be accessible through the “Investors” section of the Company's website at www.conmed.com and.

Business Wire • Jan 5, 2026

Here's Why You Should Retain CONMED Stock in Your Portfolio Now

CONMED gains momentum from high-margin platforms and supply-chain recovery, even as tariffs and dV5 adoption weigh on near-term margins.

Zacks Investment Research • Dec 31, 2025

Why Conmed (CNMD) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Dec 30, 2025

Here's Why Conmed (CNMD) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Dec 15, 2025

Here's Why Conmed (CNMD) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Dec 11, 2025

CONMED Stock Falls as It Strategically Exits Gastroenterology Portfolio

CNMD is set to exit its gastroenterology portfolio to streamline its focus on higher-growth surgical platforms and boost long-term margins.

Zacks Investment Research • Dec 8, 2025

Why Is Conmed (CNMD) Up 0.1% Since Last Earnings Report?

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 5, 2025